Latest filing published 03 Nov 2026 for Rapport Therapeutics, Inc., €4.5M.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +9.6%Entry US$20.02 · Close at T+365 US$21.94
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Third Rock Ventures V, L.P.: trading record in brief
Third Rock Ventures V, L.P. has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Septerna, Inc., Rapport Therapeutics, Inc. and CARGO Therapeutics, Inc. In total, 14 filings cover trades dated from 14 November 2023 to 30 October 2026.
Market trades split into 3 purchases (€29.5M) and 3 sales (€21.0M). The net balance comes to €8.5M on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants. 2026 to date brings no purchases and 3 sales.
A typical purchase (the median) is worth €6.2M. 1 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The latest filing, published on 3 November 2026, reports a share grant of €4.5M in Rapport Therapeutics, Inc. The latest purchase dates back some time: it was published 750 days ago, on 28 October 2024. The median gap between trade and publication is zero days: most filings appear on the same day. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Third Rock Ventures V, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 238,095 shares@ US$21.000.34% mcap10.8% of flowCommon StockSEC:0001193125-26-445438:0
- 1,190,476 shares@ US$21.001.69% mcap54.0% of flowCommon StockSEC:0001193125-26-445438:1
- 147,059 shares@ US$50.270.36% mcap27.0% of flowCommon StockSEC:0001193125-26-352692:0
- 141 shares@ US$51.080.0003% mcap0.0% of flowCommon StockSEC:0001193125-26-352692:1
- 426,005 shares@ US$40.3170.88% mcap100.0% of flowCommon StockSEC:0001193125-26-167636:0
- 2,872,956 shares0Common StockSEC:0000950170-24-117772:1
- 370,500 shares@ US$18.0026.0% of flowCommon StockSEC:0000950170-24-117772:2Canonical exit: 26 Jan 2025 (T+90)
- 279,500 shares@ US$18.0019.6% of flowCommon StockSEC:0000950170-24-117772:3Canonical exit: 26 Jan 2025 (T+90)
- 4,790,773 shares0Common StockSEC:0000950170-24-117772:0
- 969,218 shares0Common StockSEC:0000950170-24-071537:1
- 6,551,449 shares0Common StockSEC:0000950170-24-071537:0
- 473,786 sharesCommon StockSEC:0000899243-23-020350:1
- 1,333,333 shares@ US$15.00100.0% of flowCommon StockSEC:0000899243-23-020350:2Canonical exit: 12 Feb 2024 (T+90)
- 1,737,216 sharesCommon StockSEC:0000899243-23-020350:0
14 of 14 declarations